DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability.

1620574-24-4

C20H24F3N5O2

423.43

DMSO:62.5 mg/mL (147.60 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years